Astellas Pharma (ALPMY) Earnings Date, Estimates & Call Transcripts → Must-See: Elon’s New Invention is Absolutely Insane (From InvestorPlace) (Ad) Free ALPMY Stock Alerts $9.48 -0.20 (-2.07%) (As of 05/17/2024 08:54 PM ET) Add Compare Share Share EarningsStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort Interest Earnings SummaryLatest Earnings DateApr. 25EstimatedActual EPS (Apr. 25) $0.11 Beat By $0.11 Skip Charts & View Estimated and Actual Earnings DataEarnings Per ShareRevenueALPMY Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.ALPMY Estimated and Actual Revenue by Quarter Estimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad InvestorPlaceCrypto Pioneer Says: “The last crypto bull market has begun.”Right now, there’s over $6 trillion in potential investment money waiting on the sidelines. That means this crypto bull market has a lot more room to run before it comes close to being a bubble.Click here if you’d like to learn more about these five cryptos… Astellas Pharma Analyst EPS EstimatesCurrent Year EPS Consensus Estimate:$0.44 EPSNext Year EPS Consensus Estimate: $0.86 EPSALPMY Earnings Date and InformationAstellas Pharma last posted its quarterly earnings data on April 25th, 2024. The reported $0.11 EPS for the quarter. The company had revenue of $2.79 billion for the quarter. Astellas Pharma has generated $0.07 earnings per share over the last year ($0.07 diluted earnings per share) and currently has a price-to-earnings ratio of 135.4. Earnings for Astellas Pharma are expected to grow by 95.45% in the coming year, from $0.44 to $0.86 per share. Read More Astellas Pharma Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript4/25/2024Q4 2024-$0.11+$0.11$0.34-$2.79 billion2/5/2024Q3 2024-$0.12+$0.12$0.17-$2.86 billion11/1/2023Q3 2023$0.17($0.01)($0.18)($0.01)-$2.71 billion 8/1/2023Q2 2023$0.22$0.13($0.09)$0.13-$2.73 billion4/27/2023Q4 2023-$0.15+$0.15$0.49-$2.68 billion2/6/2023Q3 2023-$0.27+$0.27$0.35-$2.85 billionElon to Transform U.S. Economy? (Ad)A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.One company holds a near-total monopoly on it.10/31/2022Q2 2023-$0.28+$0.28$0.28-$2.76 billion8/1/2022Q1 2023-$0.10+$0.10$0.10-$2.95 billion4/27/2022Q4 2022-($0.04)($0.04)($0.04)-$2.62 billion2/2/2022Q3 2022-$0.34+$0.34$0.39-$3.00 billion10/29/2021Q2 2022-$0.20+$0.20$0.20-$2.96 billion7/30/2021Q1 2022-$0.15+$0.15$0.15-$2.98 billion Astellas Pharma Earnings - Frequently Asked Questions When did Astellas Pharma announce their last quarterly earnings? Astellas Pharma (OTCMKTS:ALPMY) last announced its quarterly earning data on Thursday, April 25, 2024. Learn more on ALPMY's earnings history. How much revenue does Astellas Pharma generate each year? Astellas Pharma (OTCMKTS:ALPMY) has a recorded annual revenue of $11.11 billion. How much profit does Astellas Pharma generate each year? Astellas Pharma (OTCMKTS:ALPMY) has a recorded net income of $118.07 million. ALPMY has generated $0.07 earnings per share over the last four quarters. What is Astellas Pharma's price-to-earnings ratio? Astellas Pharma (OTCMKTS:ALPMY) has a trailing price-to-earnings ratio of 135.43 and a forward price-to-earnings ratio of 21.55. The price/earnings-to-growth ratio is 1.64. What is Astellas Pharma's EPS forecast for next year? Astellas Pharma's earnings are expected to grow from $0.44 per share to $0.86 per share in the next year, which is a 95.45% increase. More Earnings Resources from MarketBeat Related Companies: ALNY Earnings Date TEVA Earnings Date GMAB Earnings Date BGNE Earnings Date BMRN Earnings Date VTRS Earnings Date MKGAF Earnings Date SRPT Earnings Date UTHR Earnings Date RDY Earnings Date Earnings Tools: Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country: U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Australia Earnings Reports Latest Articles: Baidu Stock Earnings Prove Ray Dalio Right about China?Home Depot: Earnings Mixed, Wait to Buy the DipTraders Sell but Investors Still Win After Palantir's EarningsTech Earnings Insights: Where Opportunity Meets UncertaintyApple’s Earnings Show Investors Its Strength and Its WeaknessCarvana’s Q1 Earnings: A Profitability U-TurnPayPal’s Strong Earnings Growth and Strategic Evolution This page (OTCMKTS:ALPMY) was last updated on 5/20/2024 by MarketBeat.com Staff From Our PartnersThe Overlooked Retirement Asset You Probably Don’t OwnCrypto 101 MediaElon’s New Device is About to Shock the WorldInvestorPlaceBiden Nomination CANCELED?The Freeport SocietyShocking: One AI startup's revenue could surge 4,735%Manward PressUrgent Nvidia WarningAltimetry"The Biggest Drug Ever" Is ComingBehind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersA once-in-a-century investment opportunityStansberry Research Adding Choose a watchlist: Watchlist My Default Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.